锡兰肉桂作为2型糖尿病潜在药物的随机对照试验研究方案
本研究为在斯里兰卡国立医院开展的一项随机、双盲、安慰剂对照临床试验方案,计划纳入210例2型糖尿病患者,随机分为两组锡兰肉桂提取物组(每组70例,剂量分别为250 mg和500 mg)和一组安慰剂组(70例),干预4个月,主要结局为糖化血红蛋白、空腹血糖和血清胰岛素。
要点
- 方案为随机双盲安慰剂对照试验,在斯里兰卡国立医院医学门诊开展,为期4个月。
- 210例2型糖尿病患者按1:1:1随机分为250 mg组、500 mg组和安慰剂组,每组70例。
- 主要结局为糖化血红蛋白、空腹血糖和血清胰岛素,次要结局包括BMI、血压和血脂等。
核心结论
- 研究结果无论阳性或阴性,均应为指导当前和未来关于糖尿病患者使用肉桂膳食补充剂的政策提供证据转变。
研究设计与样本
- 随机、双盲、安慰剂对照临床试验方案,在斯里兰卡国立医院大学医学部医学门诊开展,为期4个月。
- 计划招募210例糖尿病患者,按1:1:1区组随机分为两组试验组(每组n=70)和一组安慰剂组(n=70),随机化时按年龄、性别和疾病严重程度分层。
- 治疗药物为含锡兰肉桂提取物有效成分的胶囊,安慰剂胶囊含一水乳糖;使用250 mg和500 mg两种剂量的肉桂提取物。
- 研究药物对研究者和受试者均双盲;访视包括筛查(第0次)、1个月(第1次)、2个月(第2次)、3个月(第3次)和4个月(第4次)。
- 数据使用SPSS版本14进行分析。
关键数值与推荐
- 主要结局指标:糖化血红蛋白、空腹血浆葡萄糖和血清胰岛素。
- 次要结局指标:体质指数及其他人体测量参数、血压、总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇和甘油三酯。
- 试验注册:斯里兰卡临床试验注册中心(SLCTR),注册号SLCTR/2017/010,注册日期2017年4月5日;研究方案版本3.1,日期2017年3月21日。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous studies have explored the anti-diabetic effects of Cinnamomum cassia extract in vivo and in vitro. However, there are no studies at present exploring the effects of the indigenous species of Sri Lankan cinnamon (Cinnamomum zeylanicum) in patients with diabetes mellitus. The present study aims to evaluate the potential effects of Cinnamomum zeylanicum extract as a pharmaceutical agent in patients with type-2 diabetes mellitus. METHODS/DESIGN: The study will be conducted as a randomized, double-blind, placebo-controlled clinical trial for a period of 4 months at the Medical Clinic, University Medical Unit, National Hospital of Sri Lanka. A total of 210 subjects with diabetes, in three equal groups, will be recruited for the study. The patients will be randomized in a 1:1:1 ratio according to the method of block randomization and the subjects will be randomly and equally assigned into two test groups (n = 70 each) and one placebo group (n = 70). The population will be stratified at randomization based on age, gender and disease severity. The treatment drug is a capsule containing Cinnamomum zeylanicum extract as the active ingredient and the placebo capsule will contain lactose monohydrate. Two doses of Cinnamomum zeylanicum extracts (250 mg and 500 mg of the cinnamon extract) will be used. The study drugs will be double blinded to both investigators and participants. The visits and the evaluations will be done as follows: screening (visit 0), 1 month (visit 1), 2 months (visit 2), 3 months (visit 3) and 4 months (visit 4). The following primary outcome measures will be evaluated: glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG) and serum insulin. Secondary outcome measures include: Body Mass Index (BMI) and other anthropometric parameters, blood pressure, total cholesterol, low-density lipoprotein cholesterol (LDL), high-density lipoprotein cholesterol (HDL) and triglycerides (TAG). Data will be analyzed using SPSS version 14. DISCUSSION: We describe the protocol for a clinical trial design evaluating the effects of Cinnamomum zeylanicum (Ceylon cinnamon) in patients with type-2 diabetes mellitus. The result of the present study, positive or negative, should provide a step change in the evidence guiding current and future policies regarding the use of cinnamon dietary supplementation in patients with diabetes. TRIAL REGISTRATION: Sri Lanka Clinical Trials Registry (SLCTR), identifier: SLCTR/2017/010 ( http://slctr.lk/trials/714 ). Registered on 5 April 2017; study protocol version 3.1 21 March 2017.
引用
- Ranasinghe P, Galappaththy P, Constantine GR, et al. Cinnamomum zeylanicum (Ceylon cinnamon) as a potential pharmaceutical agent for type-2 diabetes mellitus: study protocol for a randomized controlled trial. Trials. 2017. PMID: 28962661. doi:10.1186/s13063-017-2192-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。